Biotech of the week: Kiadis Pharma, Immuno-therapy made in Amsterdam

15/01/2016 - 2 minutes


This week we say ‘auf Wiedersehen’ to Germany and head West to the Netherlands and it’s capital city, Amsterdam. This city really does have it all, whether you’re looking for history, architecture or something more indulgent… it is also the location of our biotech of the week: Kiadis Pharma

City: Amsterdam, Netherlands

Founded: 1997

Employees: 23 (as of 12/2015)

Financial Data: €167.3M Market Cap (as of 10/12/2015)


Mission: Kiadis Pharma‘s main mission is to become a leading biopharma in the research, development and commercialisation of therapeutic products in cell-based immunotherapy. They plan to achieve this by focusing on 2 main areas, leukaemia and thalassemia. At present, they have 2 product candidates, ATIR101 in blood cancers, which is currently in phase II clinical trials and ATIR201 in thalassemia, which is predictved to enter clinical development early 2016. Kiadis hope these products will provide a more effective treatment for those with these diseases,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member